Being Your Own Advocate

Published:  
05/24/2022
Categories:  
Blog - Melanoma360
 | 
Podcast
Image

In today’s busy medical practices, you need to be involved in your own care (or that of a loved one) to assure the best care. In this episode of Beyond the Clinic: Living Well With Melanoma, Melissa Wilson, PA-C, MPAS, and AIM’s “Ask a Medical Expert,” and Dr. Raymond Liu, Director of Cancer Survivorship for Kaiser Permanente San Francisco, discuss steps to help you to become your own best advocate and take control of your care.

AIM’s Melanoma Learning Center is a virtual hub for all types of melanoma education. We provide reliable, relevant, and current information about all aspects of melanoma for patients, families, healthcare professionals, caregivers, and others interested in the disease.

Recent Posts

Featured image for “The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public”
Jun. 09, 2026

The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public

Featured image for “Fifth Annual Evening in Memory of Valerie Guild”
Jun. 05, 2026

Fifth Annual Evening in Memory of Valerie Guild

Featured image for “Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective ”
Jun. 05, 2026

Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective 

Featured image for “Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes”
Jun. 05, 2026

Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes

Featured image for “Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors”
Jun. 05, 2026

Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors

Filter by Tag